New Marketing Associate Joins Colonis
We are pleased to welcome Ipek Gunhan, who brings her skills and insight to the marketing team at Colonis.
Opportunities and challenges in the future of value-added medicines
In this article we explore the opportunities that value-added medicines bring for patients and healthcare systems, along with challenges that still remain.
Our New Team Member Grows Colonis’ International Presence
We are delighted to introduce Henning Thiel, International Business Development Manager, to the Colonis team as we continue to strengthen our capabilities and accelerate our international growth ambitions.
Colonis Pharma Ltd Managing Director Becomes New Vice-Chair of the Value Added Medicines Group Within Medicines for Europe
We are excited to announce that Colonis’ Managing Director, Alan Knox, has been elected as the Vice-Chair of the Value Added Medicines Group at Medicines for Europe.
The cost of creating new medicines
How do the benefits of new medicines compare to those of value-added medicines (VAMs)? Our latest article discusses a recent study exploring the differences between the two.
Opportunities across the landscape of value-added medicines
At Colonis, we believe that innovation in value-added medicines (VAMs) is key for optimising patient outcomes. Our latest infographic explores the current landscape of VAMs, reviews the benefits to healthcare systems and patients, and considers the delivery framework needed to help transform the future of healthcare.
New Team Members Strengthen Our International Growth Ambitions
We are delighted to welcome two highly experienced new additions to our team: Melinda Bertwistle and Georgia Sullivan.
Colonis appoints new Managing Director
We are pleased to announce that Alan Knox has been appointed as the new Managing Director of the Colonis Pharma business.
Navigating regulatory approval for value-added medicines
In terms of regulatory processes and considerations, value-added medicines fall in-between generics and new chemical entities. Here, we explore the differences in regulatory pathways for value-added medicines and how they contrast with other forms of medicine.
Colonis Pharma Limited (part of the Clinigen Group of Companies), Secures Exclusive Licence and Distribution Agreement with Hyloris Pharmaceuticals for Oral Rinse XTRAZA in the UK
Colonis Pharma (part of the Clinigen group of companies), and a leader in developing and commercialising value added medicines, has announced the first and exclusive licence and distribution agreement with Hyloris Pharmaceuticals for XTRAZA(™)
(tranexamic acid), a proprietary oral rinse designed for use in dental procedures.